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Purpose of the study
ETR is potent against wild-type HIV (protein-binding
adjusted EC50 of 4 ng/mL), has a terminal elimination
half-life of 30–40 hours, and is a candidate for once-daily
(QD) dosing. In healthy volunteers, ETR AUC was similar,
Cmax was 44% higher and Cmin was 25% lower for QD vs.
twice-daily dosing (Ann Pharmacother 2008; 42: 757-65).
Once-daily DRV/r was shown to be effective and well-tol-
erated in antiretroviral (ARV)-naïve patients (AIDS 2008;
22: 1389-97). This multicenter, open-label Phase IIa trial
evaluates PK and short-term safety and efficacy of ETR 400
mg QD plus TDF/FTC 300/200 mg QD without and then
with DRV/r 800/100 mg QD.
Methods
ARV-naïve adults with HIV-1, no evidence of resistance to
study drugs, and without HBV/HCV co-infection were eli-
gible. Subjects received ETR 400 mg QD with TDF/FTC
300/200 mg QD for 14 days, then added DRV/r 800/100
mg QD on days 15–28. ETR was discontinued days 29–
42. Intensive PK sampling was performed over 24 hours
on day 14 for ETR, and day 28 for ETR, DRV and ritonavir
(RTV). All doses were administered following a meal. PK
parameters were determined using a non-compartmental
model with extravascular input and evaluated by least
squares mean (LSM) ratios with 90% confidence intervals
(CI).
Summary of results
Twenty-three subjects (20 men) enrolled: nine Black, nine
Caucasian and five Hispanic with mean age 35.9 years;
mean baseline (BL) viral load (VL) 4.2log10 copies/mL;
median BL CD4 402 cells/mm3. DRV PK was slightly
higher and RTV PK slightly lower when compared to his-
toric control (ARTEMIS week 4 PK study). Mean VL
decline was 1.7 log10 copies/mL at day 14 (n = 21) and 2.0
log10 copies/mL at day 42 (n = 20). Median CD4 increase
was 56 cells/mm3 (day 42). Most common treatment-
emergent AEs were nausea (n = 4), headache (n = 3), rash
(n = 3), and flatulence (n = 2). No serious or grade 3/4 AEs
were reported; no AEs led to discontinuation. The impact
on metabolic parameters was small when ETR was given
with or without DRV/r. (Table 1).
Conclusion
Addition of DRV/r QD to ETR QD had no significant
impact on ETR PK and exposure to ETR was adequate with
and without DRV/r. PK data and short-term safety and
efficacy support further clinical investigation of ETR 400
mg QD in HIV-1 infected patients.
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ETR ETR DRV Ritonavir
Cmax, ng/mL 790 (287) 801 (327) 7008 (1514) 465 (231)
Cmin, ng/mL 233 (130) 236 (168) 1049 (616) 27 (21)
AUC24 h, ng•h/mL 10410 (4186) 10720 (5459) 76130 (22080) 4128 (1854)
*n = 19 for AUC24 hPage 2 of 2
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